MLH1‐negative patients showed poorer chemotherapy response and had significantly longer RFS without chemotherapy compared with MLH1‐positive patients, concluding that MLH1 loss is linked to chemoresistance and suggested immune checkpoint inhibitors as a preferable treatment for MLH1‐negative gastric cancer [54]. This evidence concerns the gene MLH1 and gastric cancer.